These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33675187)

  • 1. Drug responsiveness of leukemic cells detected in vitro at diagnosis correlates with therapy response and survival in patients with acute myeloid leukemia.
    Kolesnikova MA; Sen'kova AV; Pospelova TI; Zenkova MA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1362. PubMed ID: 33675187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.
    Witte KE; Ahlers J; Schäfer I; André M; Kerst G; Scheel-Walter HG; Schwarze CP; Pfeiffer M; Lang P; Handgretinger R; Ebinger M
    Pediatr Hematol Oncol; 2011 Mar; 28(2):91-9. PubMed ID: 21214408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia.
    Reid JH; Marini BL; Benitez LL; Pettit K; Bixby DL; Burke P; Perissinotti AJ
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):393-400.e1. PubMed ID: 33612433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
    Inaba H; Coustan-Smith E; Cao X; Pounds SB; Shurtleff SA; Wang KY; Raimondi SC; Onciu M; Jacobsen J; Ribeiro RC; Dahl GV; Bowman WP; Taub JW; Degar B; Leung W; Downing JR; Pui CH; Rubnitz JE; Campana D
    J Clin Oncol; 2012 Oct; 30(29):3625-32. PubMed ID: 22965955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
    Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
    Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
    Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
    Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.
    Machaczka M; Wahlin BE; Piatkowska-Jakubas B; Rucinska M; Jurczak W; Balana-Nowak A; Klimkowska M; Hägglund H; Skotnicki AB
    Med Oncol; 2012 Sep; 29(3):2070-6. PubMed ID: 21861206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
    Martínez-Cuadrón D; Gil C; Serrano J; Rodríguez G; Pérez-Oteyza J; García-Boyero R; Jiménez-Bravo S; Vives S; Vidriales MB; Lavilla E; Pérez-Simón JA; Tormo M; Colorado M; Bergua J; López JA; Herrera P; Hernández-Campo P; Gorrochategui J; Primo D; Rojas JL; Villoria J; Moscardó F; Troconiz I; Linares Gómez M; Martínez-López J; Ballesteros J; Sanz M; Montesinos P;
    Leuk Res; 2019 Jan; 76():1-10. PubMed ID: 30468991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
    Jabbour E; Daver N; Champlin R; Mathisen M; Oran B; Ciurea S; Khouri I; Cornelison AM; Ghanem H; Cardenas-Turanzas M; Popat U; Ravandi F; Giralt S; Garcia-Manero G; Cortes J; Kantarjian H; de Lima M
    Am J Hematol; 2014 Apr; 89(4):395-8. PubMed ID: 24375514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
    Hu XM; Liu F; Zheng CM; Li L; Liu C; Zhang SS; Xiao HY; Yang XH; Wang HZ; Xu YG; Hu NP; Ma R
    Chin J Integr Med; 2009 Jun; 15(3):193-7. PubMed ID: 19568712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
    Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
    Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
    Mehta SV; Shukla SN; Vora HH
    Neoplasma; 2013; 60(6):666-75. PubMed ID: 23906301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
    Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
    Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
    ; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
    J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia.
    Fujiwara SI; Muroi K; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Ozawa K
    Hematology; 2017 Jul; 22(6):347-353. PubMed ID: 28097942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXM1 contributes to treatment failure in acute myeloid leukemia.
    Khan I; Halasi M; Patel A; Schultz R; Kalakota N; Chen YH; Aardsma N; Liu L; Crispino JD; Mahmud N; Frankfurt O; Gartel AL
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.